EyePoint Pharmaceuticals Faces Securities Class Action Lawsuit
A New York law firm has filed a class action against EyePoint Inc. over alleged securities violations affecting investors from early 2025.
Law firm Bronstein Gewirtz & Grossman, LLC has announced a securities class action lawsuit against EyePoint Pharmaceuticals Inc., traded on the Nasdaq under the ticker EYPT, targeting conduct the firm alleges harmed investors over a period of roughly 17 months.
Investors who purchased EYPT securities between March 27, 2025, and August 14, 2026, may be eligible to participate in the lawsuit and potentially recover financial losses. The lead plaintiff deadline has been set for January 19, 2027, giving affected shareholders time to come forward and join the action.
Read more Build-A-Bear Workshop Faces Securities Class Action Lawsuit →
The lawsuit seeks to recover damages from the defendants for alleged violations of federal securities law, though the specific nature of the alleged misrepresentations or omissions has not been fully detailed in the initial announcement. Class action securities cases of this type typically center on claims that a company misled investors through false or incomplete disclosures.
Shareholders are not required to have sold their shares to participate, and those who suffered losses during the defined class period are encouraged to contact the law firm directly to assess their eligibility. Appointment as lead plaintiff is not necessary to share in any potential recovery.
Continue reading at All Financial Services & Investing